Medical Cannabis Studies


• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)


• batten-disease (6)

• benefits (9)

• breast-cancer (7)


• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)


• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)


• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)


• fibromyalgia (2)

• fibrosis (1)


• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)


• health-care (1)

• hiv (7)

• huntingtons-disease (1)


• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)


• krabbe-disease (4)


• liver (2)

• lung-cancer (2)

• lupus (1)


• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)


• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)


• pain (29)

• pancreatitis (1)

• prostate-cancer (2)


• schizophrenia (2)

• skin (1)

• sports (3)


• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis (2011)

    Cannabidiol (CBD) due to its ability to control reactive gliosis in the central nervous system but without the psychotropic effects, can be a new therapeutic alternative in the treatment of inflammatory bowel diseases. View study

  • Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study (2011)

    CBD exhibits antioxidant and anti-inflammatory properties. These data highlight the anti-inflammatory and vascular stabilizing effects of CBD in endotoxic shock and suggest a possible beneficial effect of this natural cannabinoid. View study

  • Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice (2005)

    Cannabidiol acts as an agonist of the vanilloid channel 1 in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol also has potential as an antipsychotic. View study

  • Cannabidiol reverses the mCPP-induced increase in marble-burying behavior (2013)

    Cannabidiol (CBD), one of the main components of Cannabis sp., Shows clinical and preclinical anxiolytic properties. This study was based on investigating the interference of (CBD) in the effects of metachlorophenylpiperazine (mCPP), in repetitive burial. View study

  • Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2 Levels (2009)

    In this research we want to characterize the mechanisms by which cannabidi (CBD) regulates Ca 2 homeostasis and mediates neuroprotection in neuronal preparations. The results show that under pathological conditions involving mitochondrial dysfunction and Ca 2 dysregulation, (CDB) may be beneficial to avoid apoptotic signaling through the restoration of Ca 2 homeostasis. View study

  • Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug (2011)

    The results of these studies showed that cannabidiol (CBD) reduces anxiety in patients with anxiety disorders. studies can be justified in the future with new medical trials with patients with different anxiety disorders. View study

  • Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect (2013)

    According to the results obtained, it could be concluded that the non-psychoactive CBD was able to produce a significant antitumor activity both in vitro and in vivo, which suggests a possible application of CBD as an antineoplastic agent. View study

  • Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus (2012)

    This investigation was based on the evaluation of the hypothesis related to the activation of somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus (DRN) produces the antiemetic / antinausea effects of cannabidiol (CBD), a primary non-psychoactive cannabinoid that is found in cannabis. The results of this investigation show that CBD produced its antiemetic effects against nausea through the indirect activation of somatodendritic 5-HT1A autoreceptors in the DRN. View study

  • Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury (2007)

    CBD exhibits antioxidant and anti-inflammatory properties. These data highlight the anti-inflammatory and vascular stabilizing effects of CBD in endotoxic shock and suggest a potential beneficial effect of this natural cannabinoid. View study

  • Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances (2009)

    Using an animal model, this study examines the effects of CBD on the self-administration of heroin and concludes that it can be used effectively in patients with heroin addiction. View study

  • Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (2014)

    It has been shown that pure cannabidiol (CBD) has anti-inflammatory and neuroprotective properties. However, studies about the effects of CBD on epilepsy have not been conclusive. For this reason, deeper controlled studies are being planned in target intractable epilepsy populations (in patients with the Dravet and Lennox Gastaut syndromes). View study

  • Cannabidiol: Promise and Pitfalls (2014)

    This review points out a bit of the basic science theory behind the use of CBD, summarizes the published data on its clinical use for epilepsy and exposes the problems related to the use of CBD products at present. View study

  • Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. (2019)

    Pharmacological research on compounds derived from Cannabis sativa has never ended. The purpose of this review was to clarify the pharmacological activity of cannabidiol (CBD) and its multiple therapeutic applications. In addition, the critical and conflicting results of the research on the (CBD) are discussed with a focus on promising future prospects. View study

  • Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation (2012)

    In this study, a comparison between CBDA and cannabidiol, CBDA showed a markedly higher potency to inhibit vomiting in animal models. As a result, CBDA has great potential in the treatment of nausea, vomiting and anticipatory nausea for which there is currently no therapy. View study

  • Cannabidivarin is anticonvulsant in mouse and rat (2012)

    The anticonvulsant profile of cannabidivarin CBDV is investigated for the first time in invitro and in vivo models, demonstrating that it is an effective anticonvulsant without significantly affecting normal motor function. View study

  • Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism (2013)

    Botanical substances (BDS) derived from cannabis, rich in cannabidivarin (CBDV) and cannabidiol (CBD), showed anticonvulsant properties in three crisis models that were not mediated by the CB1 cannabinoid receptor. These findings support the clinical development of CBDV BDS for the treatment of epilepsy. View study

  • Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines [Internet] (2016)

    The objective of this research is to review the available published literature related to the oral spray THC: CBD for the treatment of chronic neuropathic or neuropathic pain in adults. Studies have been conducted on the therapeutic use of various synthetic cannabinoid products for the symptomatic relief of chronic pain. View study

  • Cannabinoid CB1 receptor binding and acetylcholinesterase inhibitory activity of Sceletium tortuosum L. (2010)

    In this study it was found that the unfermented alkaloid extract possesses a higher activity to bind to the CB1 receptor compared to the fermented one. The GC-MS analysis confirmed that the non-fermented alcoloid extract contains more alkaloids than the fermented one. View study

  • Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: Additional evidence (2014)

    In the present study we want to verify if interfering directly with the metabolism and reuptake of the endocannabinoids (BCE), in the pre-limbic (PL) portion of the medial prefrontal cortex (PFC) (MPFC) and dorsal HIP (dHIP) would produce different effects in Two conceptually different animal models: the highest labyrinth (EPM) and the Vogel conflict test (VCT). View study

  • Cannabinoid CB2 receptors in human brain inflammation (2008)

    The anti-inflammatory effects triggered by the activation of CB2 receptor make it an attractive target for the development of new anti-inflammatory therapies. In any case, more research is needed to corroborate the potential utility of cannabinoid-based treatments devoid of unwanted psychoactive effects View study

  • Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation (2008)

    CB2 cannabinoid receptors constitute a physiopathological mechanism for the resolution of inflammation in gastrointestinal disorders, thus being a very promising therapeutic objective. View study

  • Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with Osteoarthritis of the Knee Joint (2013)

    This study shows that cannabinoid receptors 2 (CB2) inhibit and contribute to pain relief from the prevalent joint disease, called osteoarthritis (OA). The data provided by this study provide new clinically relevant evidence that joint damage and spinal CB2 receptor expression are correlated in combination with convergent preclinical evidence that activation of CB2 receptors inhibits central sensitization and its contribution to the manifestation of chronic pain of the (OA). View study

  • Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor (2014)

    There is convergent anatomical and biochemical evidence that functional CB1 receptors are found in the mitochondria of the brain at low levels. With these data it is possible to conclude that there may be a direct relationship between the CB1 receptor and the mitochondrial functions in the brain and can be detected if certain experimental procedures are applied. View study

  • Cannabinoid Delivery Systems for Pain and Inflammation Treatment. (2018)

    This review aimed to explore the most recent developments, from preclinical to advanced clinical trials, in the field of cannabinoid administration, and focuses particularly on the treatment of pain and inflammation. Future probable directions are also considered and reported. View study